palmitoylethanolamide.com.au
HomeResearchPaul 2021

Palmitoylethanolamide: A Natural Compound for Health Management

Paul Clayton, Mariko Hill, Nathasha Bogoda, Silma Subah, Ruchitha Venkatesh. Int J Mol Sci. 2021 May 18;22(10):5305.

ReviewHumansOther animals

Design
Review
Subjects
Not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
What palmitoylethanolamide's anti-inflammatory, analgesic, antimicrobial, immunomodulatory and neuroprotective actions are, how well tolerated it is, and how delivery systems address its poor oral bioavailability

What the authors reported

PEA is well tolerated and without side effects in animals and humans, say the authors, who list applications in immunity, brain health, allergy, pain, joint health, sleep and recovery. They say PEA's poor oral bioavailability has been overcome by delivery systems now licensed as food supplements. No numbers are given.

Limits of this study

A narrative review written by authors employed by or related to Gencor Pacific, which owns the patented PEA formulations Levagen and Levagen+. The abstract gives no numbers and no study-level detail.

Source

PubMed 34069940 · doi:10.3390/ijms22105305

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.